NCT07367529 2026-01-26
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
19 trialsNCT06928922 2026-01-13
Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1 Recruiting
NCT07261098 2025-12-03
The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT07229599 2025-11-17
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2 Recruiting
NCT06945523 2025-06-04
Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT06992583 2025-05-28
Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT05000684 2025-02-20
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT06768151 2025-01-10
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT06183762 2024-09-19
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
Hunan Province Tumor Hospital
Recruiting
NCT06106152 2024-03-26
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04672356 2023-06-22
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04672369 2023-06-22
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05431569 2022-06-24
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2 Unknown
NCT04069494 2020-07-17
Descriptors and Predictors of Burden and Information Needs
Chulabhorn Cancer Center
Completed
NCT03330834 2020-07-13
CAR-T Cell Immunotherapy for Advanced Lung Cancer
Sun Yat-sen University
Phase 1 Terminated
NCT04352335 2020-07-02
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
Chung Shan Medical University
Completed
NCT03751592 2018-11-26
Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Phase 1/2 Unknown
NCT02801734 2018-03-29
EQUIP
National Cancer Centre, Singapore
Phase NA Completed